2 minute read
What It Is
Ozempic, Wegovy, and Mounjouro are GLP-1 receptor agonists originally designed for Type 2 diabetes. These medications surged in popularity for weight loss—but mounting lawsuits now allege they cause severe and painful gastrointestinal injuries, especially gastroparesis, or stomach paralysis.
What the Recall or Product Is
These drugs slow digestion to help with weight loss, but many users report intense side effects. The lawsuits claim manufacturers failed to adequately warn the public and doctors about the risk. The litigation has been consolidated into multidistrict litigation (MDL) in the Eastern District of Pennsylvania, targeting drugmakers Novo Nordisk and Eli Lilly.
What the Signature Injury Is and How It’s Hurting People
The most commonly reported injury is gastroparesis, a condition that slows or stops the stomach’s ability to move food. Symptoms include:
* Nausea and chronic vomiting
* Severe bloating and abdominal pain
* Weight loss and malnutrition
* Extended hospital stays
These injuries may require long-term treatment, surgery, or may lead to permanent disability.
Contact Us
If you or a loved one has experienced stomach paralysis or severe digestive problems after taking Ozempic, Wegovy, or Mounjouro. Call Michael Brady Lynch Firm at 888-585-5970 or email brandon@mblynchfirm.com for a free consultation.
Date: May 28, 2025
Attorney and Editor-In-Chief: Brandon Salter
Editors: Connor Wright, Kali McElroy, and Madison Hurley
Citations:
https://www.drugwatch.com/legal/ozempic-lawsuit/?utm_source=chatgpt.com
https://www.verywellhealth.com/updated-ozempic-label-notes-risk-of-intestine-blockage-8286051?utm_source=chatgpt.com
https://nypost.com/2024/09/05/health/pennsylvania-woman-juanita-gantt-claims-ozempic-nearly-killed-her/?utm_source=chatgpt.com
https://www.lawsuit-information-center.com/ozempic-gastroparesis-lawsuit.html?utm_source=chatgpt.com